Scapinin has been found to bind to cytoplasmic actin and is also a putative regulatory subunit of protein phosphatase-1 (PP1). It is found attached to the nuclear matrix-intermediate filament (NM-IF) and is down-regulated by differentiation of tumor cells. We have analyzed the genomic structure and tissue-specific expression pattern of both the human scapinin gene (PHACTR3) and the orthologous mouse gene. Both genes showed a highly conserved complex genomic organization with four different leader exons. Alternative splicing of exon 5 was found to be limited to human and variable polyadenylation in mouse transcripts only. In both species expression seems to occur predominantly in the brain. By Northern blot analysis two major transcripts in human and three transcripts in mouse were detected. Expression analysis in the mouse revealed a tissue-specific complex transcription pattern in the brain and a specific pattern was observed during prenatal development. Based on the transcriptional data we therefore assume scapinin to have a distinct biological function in the mammalian brain.

1.
Allen PB, Greenfield AT, Svenningsson P, Haspeslagh DC, Greengard P: Phactrs 1–4: A family of protein phosphatase 1 and actin regulatory proteins. Proc Natl Acad Sci USA 101:7187–7192 (2004).
2.
Altura RA, Maris JM, Li H, Boyett JM, Brodeur GM, Look AT: Novel regions of chromosomal loss in familial neuroblastoma by comparative genomic hybridization. Genes Chromosomes Cancer 19:176–184 (1997).
3.
Carninci P, Kasukawa T, Katayama S, Gough J, Frith MC, Maeda N, Oyama R, Ravasi T, et al: The transcriptional landscape of the mammalian genome. Science 309:1559–1563 (2005).
4.
Cattanach BM, Kirk M: Differential activity of maternally and paternally derived chromosome regions in mice. Nature 315:496–498 (1985).
5.
Costello JF, Fruhwald MC, Smiraglia DJ, Rush LJ, Robertson GP, Gao X, Wright FA, Feramisco JD, et al: Aberrant CpG-island methylation has non-random and tumour-type-specific patterns. Nat Genet 24:132–138 (2000).
6.
Courtois V, Chatelain G, Han ZY, Le Novere N, Brun G, Lamonerie T: New Otx2 mRNA isoforms expressed in the mouse brain. J Neurochem 84:840–853 (2003).
7.
Eden A, Gaudet F, Waghmare A, Jaenisch R: Chromosomal instability and tumors promoted by DNA hypomethylation. Science 300:455 (2003).
8.
Graveley BR: Alternative splicing: increasing diversity in the proteomic world. Trends Genet 17:100–107 (2001).
9.
Gray BA, Cornfield D, Bent-Williams A, Zori RT: Translocation (X;20)(q13.1;q13.3) as a primary chromosomal finding in two patients with myelocytic disorders. Cancer Genet Cytogenet 141:169–174 (2003).
10.
Greer JM, Puetz J, Thomas KR, Capecchi MR: Maintenance of functional equivalence during paralogous Hox gene evolution. Nature 403:661–665 (2000).
11.
Hodgson JG, Chin K, Collins C, Gray JW: Genome amplification of chromosome 20 in breast cancer. Breast Cancer Res Treat 78:337–345 (2003).
12.
Jin X, Turcott E, Englehardt S, Mize GJ, Morris DR: The two upstream open reading frames of oncogene mdm2 have different translational regulatory properties. J Biol Chem 278:25716–25721 (2003).
13.
Jones PA, Baylin SB: The fundamental role of epigenetic events in cancer. Nat Rev Genet 3:415–428 (2002).
14.
Kozak M: An analysis of vertebrate mRNA sequences: intimations of translational control. J Cell Biol 115:887–903 (1991).
15.
Medeiros LJ, Palmedo G, Krigman HR, Kovacs G, Beckwith JB: Oncocytoid renal cell carcinoma after neuroblastoma: a report of four cases of a distinct clinicopathologic entity. Am J Surg Pathol 23:772–780 (1999).
16.
Morris DR, Geballe AP: Upstream open reading frames as regulators of mRNA translation. Mol Cell Biol 20:8635–8642 (2000).
17.
Nanbru C, Prats AC, Droogmans L, Defrance P, Huez G, Kruys V: Translation of the human c-myc P0 tricistronic mRNA involves two independent internal ribosome entry sites. Oncogene 20:4270–4280 (2001).
18.
Nishizaki T, Ozaki S, Harada K, Ito H, Arai H, Beppu T, Sasaki K: Investigation of genetic alterations associated with the grade of astrocytic tumor by comparative genomic hybridization. Genes Chromosomes Cancer 21:340–346 (1998).
19.
Pendleton LC, Goodwin BL, Flam BR, Solomonson LP, Eichler DC: Endothelial argininosuccinate synthase mRNA 5′-untranslated region diversity. Infrastructure for tissue-specific expression. J Biol Chem 277:25363–25369 (2002).
20.
Reichardt W, Jung V, Brunner C, Klein A, Wemmert S, Romeike BF, Zang KD, Urbschat S: The putative serine/threonine kinase gene STK15 on chromosome 20q13.2 is amplified in human gliomas. Oncol Rep 10:1275–1279 (2003).
21.
Rugh R: The Mouse, Its Reproduction and Development. (Oxford University Press, Oxford 1990).
22.
Sagara J, Higuchi T, Hattori Y, Moriya M, Sarvotham H, Shima H, Shirato H, Kikuchi K, Taniguchi S: Scapinin, a putative protein phosphatase-1 regulatory subunit associated with the nuclear nonchromatin structure. J Biol Chem 278:45611–45619 (2003).
23.
Terada K, Ueno S, Yomogida K, Imai T, Kiyonari H, Takeda N, Yano M, Abe S, Aizawa S, Mori M: Expression of Tom34 splicing isoforms in mouse testis and knockout of Tom34 in mice. J Biochem (Tokyo) 133:625–631 (2003).
© 2006 S. Karger AG, Basel
2006
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.